

10696108

=> d his

(FILE 'HOME' ENTERED AT 11:00:42 ON 29 APR 2004)

FILE 'REGISTRY' ENTERED AT 11:00:58 ON 29 APR 2004


L1 STRUCTURE UPLOADED
L2 23 S L1
L3 STRUCTURE UPLOADED
L4 14 S L3
L5 368 S L3 SSS FULL

FILE 'CAPLUS' ENTERED AT 11:04:17 ON 29 APR 2004

L6 11 S L5

=> d 13

L3 HAS NO ANSWERS
L3 STR



Structure attributes must be viewed using STN Express query preparation.


=> d 1-11 bib abs hitstr

L6 ANSWER 1 OF 11 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:892446 CAPLUS
DN 139:364934
TI Preparation of aryl ether substituted imidazoquinolines as immune response
modifiers
IN Heppner, Philip D.; Charles, Leslie J.; Dellaria, Joseph F.; Merrill,
Bryon A.; Mickelson, John W.
PA 3M Innovative Properties Co., USA
SO U.S. Pat. Appl. Publ., 97 pp., Cont.-in-part of U.S. Ser. No. 13,202.
CODEN: USXXCO

DT Patent
LA English
FAN.CNT 11

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2003212092	A1	20031113	US 2002-165750	20020607
	US 6677348	B2	20040113		
	US 2003212091	A1	20031113	US 2001-13202	20011206
	US 6670372	B2	20031230		
	US 2004072858	A1	20040415	US 2003-675833	20030930
PRAI	US 2000-254218P	P	20001208		
	US 2001-13202	A2	20011206		
	US 2001-11921	A1	20011206		
OS	MARPAT 139:364934				
GI					

*Complete report
in 10/696753*



AB The title compds. [I; X = (CH₂)₂, CH=CH₂, etc.; R₁ = alkenyl, aryl, R₄-aryl; R₂ = H, alkyl, alkenyl, etc.; R₄ = alkyl, alkenyl which may be interrupted by one or more O atoms; R₃ = H, alkyl; n = 0-4; R = alkyl, alkoxy, OH, etc.] that contain ether and aryl or alkenyl functionality at the 1-position, and are useful as immune response modifiers, were prepared E.g., a multi-step synthesis of I [X = (CH₂)₂; R₁ = CH₂C.tplbond.CH; R₂ = H; n = 0] which showed the lowest effective concentration of 0.12 μM and 1.11 μM to induce biosynthesis of interferon α and TNFα in human cells, resp., was given. The compds. I can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases. The pharmaceutical composition comprising the compound I is claimed.

IT **437602-85-2P**
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of aryl ether substituted imidazoquinolines as immune response modifiers).

RN 437602-85-2 CAPLUS

CN 1H-Imidazo[4,5-c]quinolin-4-amine, 2-octyl-1-[2-[(3-phenyl-2-propynyl)oxy]ethyl]- (9CI) (CA INDEX NAME)

